3 results
Primary safety objective: 1) To evaluate safety of R0.6C immunizations in healthy malaria-naïve volunteers in four dose-adjuvant combinations.Primary efficacy objective:1) To assess transmission reducing activity (TRA) to mosquitoes in the standard…
The primary aim of the trial is to demonstrate the non-inferiority of CSL222 (formerly AMT-061) (2 × 1013 gc/kg) during the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-treatment (CSL222 (formerly AMT-061))…
Main study:Primary:Efficacy:- To assess the clinical outcome at 30 days follow-up after administration of a single subcutaneous injection of zalunfiban versusplacebo in STEMI subjects in the pre-hospital setting.Safety:- To assess bleeding events (…